Brokers Issue Forecasts for AMAG Pharmaceuticals, Inc.’s Q1 2018 Earnings (AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Research analysts at Leerink Swann raised their Q1 2018 earnings per share estimates for shares of AMAG Pharmaceuticals in a research report issued on Monday. Leerink Swann analyst J. Schwartz now expects that the specialty pharmaceutical company will earn ($0.80) per share for the quarter, up from their previous estimate of ($0.81). Leerink Swann has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for AMAG Pharmaceuticals’ Q2 2018 earnings at ($0.68) EPS, Q3 2018 earnings at ($2.13) EPS, Q4 2018 earnings at ($2.40) EPS, FY2018 earnings at ($6.04) EPS and FY2019 earnings at ($2.77) EPS.

A number of other brokerages have also recently issued reports on AMAG. Zacks Investment Research cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. B. Riley restated a “hold” rating and issued a $16.00 target price on shares of AMAG Pharmaceuticals in a report on Tuesday, January 16th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Morgan Stanley decreased their target price on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $15.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, January 18th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $19.89.

AMAG Pharmaceuticals (NASDAQ:AMAG) opened at $13.00 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $25.20.

Several hedge funds have recently modified their holdings of AMAG. Balter Liquid Alternatives LLC purchased a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at $120,000. Teacher Retirement System of Texas purchased a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at $162,000. Hartford Investment Management Co. purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $186,000. 361 Capital LLC purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $197,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $197,000.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/08/brokers-issue-forecasts-for-amag-pharmaceuticals-inc-s-q1-2018-earnings-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply